Utibron

Drooling, peripheral muscarinic effects, cardiac vagal inhibitory reflexes + 16 more

Treatment

20 Active Studies for Utibron

What is Utibron

Glycopyrronium

The Generic name of this drug

Treatment Summary

Indacaterol is a medication used to treat asthma and chronic obstructive pulmonary disease (COPD). It is taken once a day and acts quickly to open up the airways. Indacaterol is sold in Europe under the brand name Onbrez and in the United States under the brand name Arcapta Neohaler. This medication is provided in its maleate salt form, with only the pure R-enantiomer being dispensed.

Robinul

is the brand name

image of different drug pills on a surface

Utibron Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Robinul

Glycopyrronium

1961

294

Effectiveness

How Utibron Affects Patients

Bronchodilator drugs help open up the airways for people with chronic obstructive pulmonary disease. Indacaterol is a long-lasting bronchodilator that can be taken just once a day. It is 35% more effective than salmeterol, the most common bronchodilator. The most common side effect of indacaterol is a short-lasting cough that usually begins 15 seconds after taking the drug and goes away after 6 seconds. This cough does not cause any other problems, and is no more severe than other bronchodilators.

How Utibron works in the body

Indacaterol helps to relax and open the airways in asthma and COPD. This is done by stimulating receptors in the smooth muscle of the airways which cause them to relax. Indacaterol binds very strongly to these receptors, allowing it to work quickly and for a long time. It also increases concentrations of cyclic AMP, which helps relax the airways even further. Indacaterol is more active on beta2-receptors compared to beta1- and beta3-receptors, making it more effective at relaxing the airways.

When to interrupt dosage

The recommended dose of Utibron is based on the established condition, including Chronic Obstructive Pulmonary Disease (COPD), Maintenances and symptoms poorly managed by inhaled corticosteroids. The amount of dosage fluctuates, depending on the technique of delivery outlined in the accompanying table.

Condition

Dosage

Administration

Drooling

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Increased upper airway secretion

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Induction of anesthesia therapy

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Choking

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Bronchitis, Chronic

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Peptic Ulcer

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

General Surgery

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Cerebral Palsy

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Hyperhidrosis disorder

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Oral cavity

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Anticholinergic Syndrome

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Reflex, Trigeminocardiac

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Reflex, Trigeminocardiac

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Chronic Obstructive Pulmonary Disease

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

peripheral muscarinic effects

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

cardiac vagal inhibitory reflexes

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Bodily secretions

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Emphysema

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Neurological Conditions

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Warnings

Utibron Contraindications

Condition

Risk Level

Notes

Ulcerative Colitis

Do Not Combine

Uterine Inertia

Do Not Combine

Ulcerative Colitis

Do Not Combine

Myasthenia Gravis

Do Not Combine

Arterial Occlusive Diseases

Do Not Combine

Cardiovascular Physiological Phenomena

Do Not Combine

Pulse Frequency

Do Not Combine

Therapeutic procedure

Do Not Combine

Intestinal Pseudo-Obstruction

Do Not Combine

Open-angle glaucoma

Do Not Combine

Uropathy Obstructive

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Glycopyrronium may interact with Pulse Frequency

There are 20 known major drug interactions with Utibron.

Common Utibron Drug Interactions

Drug Name

Risk Level

Description

Aclidinium

Major

The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Aclidinium.

Cimetropium

Major

The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Cimetropium.

Eluxadoline

Major

The risk or severity of constipation can be increased when Glycopyrronium is combined with Eluxadoline.

Macimorelin

Major

The therapeutic efficacy of Macimorelin can be decreased when used in combination with Glycopyrronium.

Secretin human

Major

The therapeutic efficacy of Secretin human can be decreased when used in combination with Glycopyrronium.

Utibron Toxicity & Overdose Risk

Taking too much indacaterol may cause symptoms like chest pain, high or low blood pressure, rapid heartbeat, anxiety, headache, shaking, thirst, palpitations, muscle cramps, nausea, dizziness, tiredness, feeling unwell, low potassium levels, high blood sugar, metabolic acidosis, and difficulty sleeping. In severe cases, it can lead to cardiac arrest and death.

image of a doctor in a lab doing drug, clinical research

Utibron Novel Uses: Which Conditions Have a Clinical Trial Featuring Utibron?

243 active trials are being conducted to assess the utility of Utibron in treating Asthma symptoms inadequately controlled with inhaled corticosteroids as well as Chronic Obstructive Pulmonary Disease (COPD).

Condition

Clinical Trials

Trial Phases

Chronic Obstructive Pulmonary Disease

77 Actively Recruiting

Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Choking

4 Actively Recruiting

Not Applicable

General Surgery

2 Actively Recruiting

Not Applicable

Hyperhidrosis disorder

0 Actively Recruiting

Increased upper airway secretion

0 Actively Recruiting

Anticholinergic Syndrome

0 Actively Recruiting

Induction of anesthesia therapy

0 Actively Recruiting

Reflex, Trigeminocardiac

0 Actively Recruiting

Emphysema

4 Actively Recruiting

Phase 2, Not Applicable

Oral cavity

0 Actively Recruiting

peripheral muscarinic effects

0 Actively Recruiting

Reflex, Trigeminocardiac

0 Actively Recruiting

Drooling

0 Actively Recruiting

Neurological Conditions

1 Actively Recruiting

Not Applicable

Bronchitis, Chronic

0 Actively Recruiting

cardiac vagal inhibitory reflexes

0 Actively Recruiting

Peptic Ulcer

0 Actively Recruiting

Bodily secretions

0 Actively Recruiting

Cerebral Palsy

0 Actively Recruiting

Utibron Reviews: What are patients saying about Utibron?

5

Patient Review

5/27/2019

Utibron for Bronchospasm Prevention with COPD

This is by far the best medication I have ever used. There are hardly any side effects and I don't have to use my rescue inhaler as much.

5

Patient Review

11/18/2018

Utibron for Prevention of Bronchospasms with Emphysema

Utibron has been a revelation for me. I'm breathing better and have more energy than I have in months.

4

Patient Review

9/16/2016

Utibron for Bronchospasm Prevention with COPD

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about utibron

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Bevespi prescribed for?

"This medicine is for use in adults 18 years of age and older.

Bevsepi Aerosphere is a prescription medicine used to treat chronic obstructive pulmonary disease (COPD). COPD includes chronic bronchitis, emphysema, or both. Bevsepi Aerosphere is used as 2 inhalations, 2 times each day in the morning and in the evening, to improve symptoms of COPD for better breathing.

This medicine is for use in adults 18 years of age and older."

Answered by AI

What is Utibron neohaler?

"USING UTIBRON NEOHALER

UTIBRON NEOHALER is indicated for the long-term, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. The recommended dose is 75 mcg of indacaterol and 21 mcg of glycopyrrolate inhaled once daily.

Patients should use UTIBRON NEOHALER at the same time each day. UTIBRON NEOHALER can be used with or without food."

Answered by AI

Who makes Utibron?

"Sunovion is committed to expanding its heritage of advancing new treatments for serious respiratory medical conditions, including the 15.7 million people in the U.S. who suffer from COPD."

Answered by AI

What is UTIBRON?

"Utibron Neohaler is a prescription medicine used to treat the symptoms of Chronic Obstructive Pulmonary Disease (COPD). Utibron Neohaler is typically used in conjunction with other medications."

Answered by AI

Clinical Trials for Utibron

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+
All Sexes
Stanford, CA

Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.

Waitlist Available
Has No Placebo

Stanford University

Jeff Swigris, DO, MS

Minnesota Health Solutions

Have you considered Utibron clinical trials?

We made a collection of clinical trials featuring Utibron, we think they might fit your search criteria.
Go to Trials

Have you considered Utibron clinical trials?

We made a collection of clinical trials featuring Utibron, we think they might fit your search criteria.
Go to Trials
Image of Cleveland Clinic Foundation in Cleveland, United States.

Multidisciplinary Clinic Evaluation for Sarcopenia Due to COPD

18+
All Sexes
Cleveland, OH

Sarcopenia, or skeletal muscle loss, impacts up to 40% of COPD patients and is a major cause for morbidity and mortality. Despite the high clinical significance of sarcopenia in COPD, the diagnosis remains elusive because accurate measures of skeletal muscle are not tested during routine clinical care. The goal is to use evidence-based strategies to diagnose and treat sarcopenia due to COPD. The multidisciplinary team includes a pulmonologist, pharmacist, COPD nurse, and COPD coordinator. The investigators anticipate that the approach will improve clinical outcomes for COPD patients with sarcopenia as compared to standard of care visits in ambulatory COPD clinics. The investigators will determine if the approach improves skeletal muscle mass and function, and also improves clinical outcomes related to frequency of hospitalization or ED (Emergency Department) visits, COPD exacerbations, and mortality.

Recruiting
Has No Placebo

Cleveland Clinic Foundation

Amy Attaway, MD

Image of Duke Asthma Allergy and Airway Center in Durham, United States.

Inhaled Treprostinil for Chronic Obstructive Pulmonary Disease

18+
All Sexes
Durham, NC

The goal of this clinical trial is to evaluate whether inhaled Treprostinil (Tyvaso) can improve oxygen delivery and blood flow in the lungs in adults (age ≥40) with chronic obstructive pulmonary disease (COPD) and hypoxemia who have less severe reduction in lung blood volume (diffusing capacity of the lungs for carbon monoxide \[DLCO\] ≥45%). The main questions it aims to answer are: 1. Does inhaled Treprostinil increase pulmonary capillary blood volume in ventilated lung regions, as measured by hyperpolarized xenon-129 magnetic resonance imaging (HP129Xe MRI)? 2. Does inhaled Treprostinil improve oxygen delivery (measured as red blood cell \[RBC\] chemical shift) and maintain or only slightly change pulmonary vascular resistance (measured by RBC oscillation amplitude)? 3. Can pre-treatment MRI parameters (RBC transfer and RBC oscillation amplitude) predict who will respond to inhaled Treprostinil? Participants will: * Use the Tyvaso nebulizer (inhaled Treprostinil) 4 times daily for 4 weeks, starting at 3 breaths per session and increasing to a maximum of 6 breaths per session as tolerated. * Undergo HP129Xe MRI before and after treatment to assess regional lung function and oxygen exchange. * Complete pulmonary function tests (PFTs), 6-minute walk tests (6MWT), and echocardiograms at the beginning and end of the study. * Be monitored for adverse events, with a phone check-in midway through and after the treatment period.

Phase 2
Recruiting

Duke Asthma Allergy and Airway Center

United Therapeutics

Image of Duke University Hospital in Durham, United States.

Photon-counting CT for Chronic Obstructive Pulmonary Disease

Any Age
All Sexes
Durham, NC

Purpose and objective: This project aims to evaluate photon-counting computed tomography (PCCT) quantitative accuracy using COPDGene subjects. The goal is to establish acquisition protocols for PCCT scans with proper post-processing (e.g., reconstruction parameters and harmonization techniques) that enable reproducible measurements of emphysema metrics (e.g., Perc15, LAA-950, HU accuracy) and airways (Pi10, WA%) in the lungs. Study activities and population group: The study will recruit subjects from a current study at Duke (COPDGene Phase 4, Pro00113442). Here are the aims: * The research team will request consent from participants to acquire PCCT scans at their Phase 4 COPDGene visit. Scans will be performed using a PCCT-specific protocol. * Reconstruct the PCCT images with multiple post-acquisition parameter settings. Apply harmonization techniques that are recently developed by the investigators of this study. Data analysis: * Identify the reconstruction and harmonization conditions that enable reproducible measurements of emphysema metrics (perc15, LAA-950, HU accuracy) and airways (Pi10, WA%), when compared to the counterpart EICT scans. * Demonstrate the non-inferiority and potentially improved capabilities of PCCT scans in cross-sectional and longitudinal studies. Risk/safety issues: The participants are asked to get an additional CT scan with a PCCT scanner at their COPDGene Phase 4 visit. This additional CT scan will be done using an inspiratory chest protocol with a total of 3 mGy (\~1.5 mSv) radiation dose. This is roughly equivalent of 6 month of background radiation. Women who are pregnant will not have a chest CT scan done until they are confirmed to be not pregnant.

Recruiting
Has No Placebo

Duke University Hospital

Ehsan Abadi, Ph.D.

Have you considered Utibron clinical trials?

We made a collection of clinical trials featuring Utibron, we think they might fit your search criteria.
Go to Trials